If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...
Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.
A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...
UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...
Amarillo Globe-News on MSN9d
What are Zephyr Valves? Groundbreaking COPD treatment brings hope to Panhandle patientsAfter waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...
Researchers have identified new lung function and blood test cutoffs to improve timely chronic hypercapnia management in ...
Hosted on MSN1mon
Pharmac funds new cancer, RSV, COPD treatmentsLung Cancer Foundation head Philip Hope said the announcement met the greatest treatment need right ... inhaler is expected to help 5000 New Zealanders with COPD in the first year of funding ...
Hosted on MSN2mon
First new treatment for asthma and COPD in half a century—new studyFor decades, the standard treatment for these potentially ... benralizumab could become the first new therapy approved for eosinophilic exacerbations of asthma and COPD in over 50 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results